12 active not recruiting, 10 recruiting, 7 completed, 4 terminated. 19 Phase 2, 10 Phase 1, 6 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow B Acute Lymphoblastic Leukemia: new trials by email Literature Review of B Acute Lymphoblastic Leukemia trials Research Report on B Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia Activity Tracking, Biospecimen Collection, Cognitive Assessment - Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia | Not applicable | Recruiting | University of Washington | 50 | 2025-10-15 | 2026-08-19 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia JY231 Injection - B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma | Not applicable | Recruiting | Affiliated Hospital of Guangdong Medical University | 20 | 2025-05-30 | 2025-06-10 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia JY231 Injection - B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma | Not applicable | Recruiting | Shenzhen Genocury Biotech Co., Ltd. | 20 | 2025-03-01 | 2025-05-15 |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). Azacitidine Injection, Venetoclax, CD19CD22 CAR-T - B Acute Lymphoblastic Leukemia, Ph-Negative ALL | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2024-04-20 | 2024-04-22 |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
| Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia Cyclophosphamide, Vincristine, Dexamethasone - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 68 | 2023-06-09 | 2026-07-10 |
| CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission Autologous Anti-CD19 CAR-expressing T Lymphocytes, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2023-04-26 | 2026-10-08 |
| Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ), Nivolumab starting at day -1 - B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 26 | 2023-03-15 | 2024-05-29 |
| Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL Blinatumomab - B Acute Lymphoblastic Leukemia | Phase 2 | Completed | Chen Suning | 35 | 2022-09-08 | 2024-09-19 |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) - B-Cell Lymphoma, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | John Lister | 30 | 2022-04-19 | 2025-01-13 |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2022-03-17 | 2026-05-28 |
| Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia Minimal residual disease (MRD) monitoring - B Acute Lymphoblastic Leukemia | Unknown | Sun Yat-sen University | 255 | 2021-01-30 | 2021-07-27 | |
| TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) PBLTT52CAR19 - B Acute Lymphoblastic Leukemia | Phase 1 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 9 | 2020-08-12 | 2024-03-07 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation Allogeneic Bone Marrow Transplantation, Bendamustine, Filgrastim-sndz - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2019-10-28 | 2026-04-15 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-11-02 |
Showing 20 of 39. Sign in to see all of them.
Burkitt Lymphoma (39) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Leukemia, Biphenotypic, Acute (7) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (6) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Neoplasm, Residual (4) · Lymphoma (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Down Syndrome (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1)
DNA Virus Infections (39) · Epstein-Barr Virus Infections (39) · Hemic and Lymphatic Diseases (39) · Herpesviridae Infections (39) · Immune System Diseases (39) · Immunoproliferative Disorders (39) · Infections (39) · Lymphatic Diseases (39) · Lymphoma, Non-Hodgkin (39) · Lymphoproliferative Disorders (39) · Neoplasms (39) · Neoplasms by Histologic Type (39) · Tumor Virus Infections (39) · Virus Diseases (39) · Lymphoma, B-Cell (38)
Cyclophosphamide (17) · Methotrexate (15) · Vincristine (15) · Mercaptopurine (14) · Cytarabine (13) · merphos (13) · Doxorubicin (12) · Prednisone (12) · azathiopurine (12) · Dexamethasone (11) · deltacortene (11) · prednylidene (11) · Specimen Handling (10) · blinatumomab (10) · Calcium Dobesilate (9)
National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (5) · Children's Oncology Group (3) · City of Hope Medical Center (3) · University of Washington (3) · Alliance for Clinical Trials in Oncology (2) · Stanford University (2) · Affiliated Hospital of Guangdong Medical University (1) · Assistance Publique - Hôpitaux de Paris (1) · Autolus Limited (1) · Chen Suning (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · John Lister (1) · OHSU Knight Cancer Institute (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1)
United States (27) · Canada (8) · Puerto Rico (8) · China (7) · Australia (6) · New Zealand (4) · France (3) · Switzerland (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · Finland (1) · Germany (1)
Elias Jabbour (4) · Ibrahim Aldoss (3) · Ryan Cassaday (2) · Ajay Vora, Prof, MD (1) · Andrea Biondi (1) · Anjali S Advani (1) · Anna Halpern, MD (1) · Aref Al-Kali (1) · Crystal Mackall (1) · Erin H Breese (1) · Etan Orgel (1) · Huang Jianzhang, Doctor (1) · Ibrahim T Aldoss (1) · Issa F Khouri (1)
PMID 41671463, PMID 35622074, PMID 42341322, PMID 32496902, PMID 32589970, PMID 32692850, PMID 32772769, PMID 32929049, PMID 33191168, PMID 33844429, PMID 34312556, PMID 34515338, PMID 34889384, PMID 35713551, PMID 36279879, PMID 36288281, PMID 36322825, PMID 36821767, PMID 37879077, PMID 37890117, PMID 37960985, PMID 38551807, PMID 38867582, PMID 38968138, PMID 39121442, PMID 39218935, PMID 39651791, PMID 39984805
U10CA180886 (7), P30CA015704 (2), P30CA033572 (2), U10CA180821 (2), U10CA180888 (2), 2016 (1), 2017 (1), N01CM00099 (1), P30CA016672 (1), U10CA098543 (1), U24CA196173 (1), UG1CA189955 (1), UM1CA186686 (1)